Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer

Immune checkpoint inhibitors have become the standard of care in the treatment of metastatic non-small-cell lung cancer (NSCLC). The combination of nivolumab plus ipilimumab and chemotherapy has been shown to improve outcomes in terms of overall survival (OS) and progression-free survival (PFS). The...

Descripción completa

Detalles Bibliográficos
Autores principales: Shalata, Walid, Yakobson, Alexander, Dudnik, Yulia, Swaid, Forat, Ahmad, Mohammad Sheikh, Abu Jama, Ashraf, Cohen, Ahron Yehonatan, Agbarya, Abed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525289/
https://www.ncbi.nlm.nih.gov/pubmed/37760878
http://dx.doi.org/10.3390/biomedicines11092438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525289/
https://www.ncbi.nlm.nih.gov/pubmed/37760878
http://dx.doi.org/10.3390/biomedicines11092438

Ejemplares similares